This article was originally published in The Gray Sheet
Executive SummaryManufacturer of immunological reagents, test kits and oligonucleotides for biomedical research withdraws planned follow-on offering of 4 mil. shares "due to recent market conditions," the firm announces May 4. The Camarillo, California company had filed a registration statement for the offering with the Securities and Exchange Commission on March 22 (1"The Gray Sheet" April 3, p. 22)
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.